What are the Key Drivers in the Plasma Fractionation Market?

A prominent driver is the increasing number of primary immunodeficiency, autoimmune diseases, and haemophilia, which are fueling demand for plasma-derived therapies. Alongside, the involvement of many key players in their expansion of plasma collection centers and inventories, which fulfil the rising demand for plasma. Continuous developments in higher-concentration immunoglobulins and new hyperimmune globulins that target developing infectious diseases are also impacting the overall market growth.

What are the Major Trends in the Plasma Fractionation Market?

• In October 2025, Biolab Holdings, Inc., a Phoenix-based medical manufacturer specialising in wound care products, entered into its strategic investment and commercialization partnership with Terraplasma Medical GmbH, a German company innovating the development of plasmapax, a portable cold atmospheric plasma (CAP) device.
• In August 2025, GC Biopharma, a South Korean biopharmaceutical company, signed a Memorandum of Understanding (MoU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the manufacturing of plasma-derived medicinal products.
• In March 2025, Kenox Pharmaceuticals and Lactiga US partnered to boost the progression of new mucosal-targeted secretory IgA (sIgA) therapies, aiming to escalate immunity for immunodeficient individuals.
  

What is the Emerging Challenge in the Plasma Fractionation Market?

The market is mainly facing a hurdle is a limited and often unstable supply of plasma. In some cases, the market faces the generation of blood wastage, regulatory obstacles to new market entrants, and the restricted availability of some required plasma products, especially in regions like India.

Segmental Insights

By type analysis

Which Type Led the Plasma Fractionation Market in 2024?

The immune globulin segment accounted for a dominant share of the market in 2024. This type usually possesses a wider range of applications in chronic inflammatory conditions and blood disorders, which boosts demand. Whereas, various pharmaceutical companies are increasingly investing in and emerging novel intravenous (IVIg) and subcutaneous (SCIG) immunoglobulin formulations.

However, the coagulation factor segment is predicted to expand at a lucrative CAGR. Nowadays, researchers are emphasising the elimination of prions, improving FVIII and IX purity, expanding prothrombin complex products, and demonstrating the roles of factors like FXII in coagulation. The latest chromatography is supporting the purification of fibrinogen, and fibrin sealants are now developed by integrating purified fibrinogen and thrombin concentrates.

By application type analysis

What Made the Hospital Segment Dominant in the Market in 2024?

The hospital segment held a major revenue share of the plasma fractionation market in 2024. The globe is facing a major rise in chronic diseases, surgical procedures, and the rising demand for plasma-derived therapies. Additionally, hospitals provide vital treatments, such as IVIg and albumin, for immune deficiencies, liver diseases, and trauma cases. As well as continuous optimisations in plasma collection, storage, and fractionation technologies are impacting the accessibility and availability of plasma treatments in hospitals.

On the other hand, the retail pharmacy segment is estimated to expand rapidly in the predicted timeframe. Ongoing greater government investments in healthcare infrastructures, the accelerating use of plasma-derived therapies, which are easily available in these pharmacies, are boosting the ultimate expansion. A pharmacist of these pharmacies possesses the knowledge regarding the proper storage and handling of these fragile products, some of which are packaged as pre-filled syringes or ready-to-use vials.

What are the Revolutionary Developments in the Plasma Fractionation Market?

• In August 2025, Kedrion received the grant from the US Food and Drug Administration (FDA) Orphan Drug Designation for an investigational plasma-derived treatment for Congenital Aceruloplasminemia.
• In August 2025, Kamada Ltd., a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved the supplement to its existing Biologics License Application (BLA) for Kamada Plasma's collection center in Houston, TX.
• In June 2025, Takeda received the U.S. Food and Drug Administration (FDA) approval for GAMMAGARD LIQUID ERC [immune globulin infusion (human)] as replacement therapy for people two years of age and older with primary immunodeficiency (PI).
  

Browse More Insights of Towards Healthcare:

The global cold plasma market

The specialty control plasma market

The blood bank and plasma freezer market

The plasma protein products market

The plasma-derived medicine market

The blood plasma freezer market

The blood plasma fractionation market

Plasma Fractionation Market Key Players List

• Syntegon
• CSL Behring
• Grifols Therapeutics
• Mitsubishi Tanabe
• Octapharma AG
• Hualan Bio
• Kedrion S.p.A
• Takeda Pharmaceutical Company Ltd.
• LFB Group
• Intas Pharmaceuticals Ltd.
• Biotest AG
• Bio Product Laboratory Ltd.

Download the Competitive Landscape market report @

Segments Covered in this Report

By Type

• Albumin
• Immune Globulin
• Coagulation Factor
• Others

By Application

• Hospital
• Retail Pharmacy
• Other
  

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
    

Immediate Delivery Available | Buy This Premium Research @

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard:

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research

You can place an order or ask any questions, please feel free to contact us at ...

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web:

Our Trusted Data Partners

Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest